This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
IceCure Medical (ICCM) delivered earnings and revenue surprises of 14.29% and 12.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
60 Degrees Pharmaceuticals Inc. (SXTP) delivered earnings and revenue surprises of -6.82% and 13.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
GoodRx Holdings, Inc. (GDRX) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
GoodRx (GDRX) delivered earnings and revenue surprises of -11.11% and 0.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories (CRL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 17.15% and 0.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Progyny (PGNY) Beats Q2 Earnings Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 19.44% and 1.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint
by Zacks Equity Research
IceCure's (ICCM) ProSense cryoablation system demonstrated a 100% complete ablation rate for breast cancer per a study published in "Cancers."
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod
by Zacks Equity Research
IceCure Medical's (ICCM) XSense Cryoablation System receives FDA approval, marking a pivotal step in minimally-invasive tumor treatment across multiple medical fields
IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
IceCure Medical (ICCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Doximity (DOCS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 25% and 1.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ReWalk Robotics (LFWD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ReWalk (LFWD) delivered earnings and revenue surprises of -4.29% and 4.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
The Oncology Institute (TOI) delivered earnings and revenue surprises of -83.33% and 0.53%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
DocGo Inc. (DCGO) Matches Q1 Earnings Estimates
by Zacks Equity Research
Motion Acquisition (DCGO) delivered earnings and revenue surprises of 0% and 3.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Ascend Wellness Holdings, Inc. (AAWH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ascend Wellness Holdings, Inc. (AAWH) delivered earnings and revenue surprises of -80% and 1.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Revvity (RVTY) delivered earnings and revenue surprises of 4.26% and 0.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA
by Zacks Equity Research
IceCure Medical (ICCM) submits final ICE data along with multiple sub-analysis to the FDA seeking approval for marketing authorization for treating early-stage breast cancer.
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
IceCure Medical Ltd. (ICCM) delivered earnings and revenue surprises of 0% and 65.58%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -29.17% and 73.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Nutex Health Inc. (NUTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nutex Health Inc. (NUTX) delivered earnings and revenue surprises of 0% and 5.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
IceCure Medical Ltd. (ICCM) delivered earnings and revenue surprises of 11.11% and 25.26%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
LumiraDx Limited (LMDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
LumiraDx Limited (LMDX) delivered earnings and revenue surprises of 6.67% and 17.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MDxHealth SA Sponsored ADR (MDXH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MDxHealth SA Sponsored ADR (MDXH) delivered earnings and revenue surprises of 87.50% and 6.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of 13.04% and 45.27%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
The Beauty Health Company (SKIN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
The Beauty Health Company (SKIN) delivered earnings and revenue surprises of -100% and 3.90%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Apollo Medical Holdings, Inc. (AMEH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Apollo Medical Holdings, Inc. (AMEH) delivered earnings and revenue surprises of 20% and 1.70%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
1,000% Move in a Day: Medical Stock Soars on Positive Data
by Andrew Rocco
IceCure Medical, a little-known medical device company surged in after-hours trading Monday. IceCure's Prosense technology proved to be a safe and effective treatment for cancerous kidney tumors.